Shuiying Hu

Image
Shuiying Hu

Shuiying Hu

Title
Research Assistant Professor
Unit / Department / Division
Pharmaceutics and Pharmacology
Address
406 Biomedical Research Tower
Email Address

Professional Interests

Professional Interests

Dr. Hu’s research interests include drug development and translational cancer pharmacology, and her current projects are focused on the development of transport modulators that could be used in conjunction with neurotoxic chemotherapy. The overall goal of her research is to evaluate the role of solute carriers in cancer drug-induced toxicity profiles, in particular peripheral neuropathy. In addition, she aims to identify chemical inhibitors of critical transporters, and explore novel strategies to ameliorate the incidence and severity of debilitating side effects of cancer drugs.

Education

  • PhD, Pharmaceutical Sciences, West Virginia University

Honors

  • Dean's Innovative Research Award, 2019

Journal Articles

  • Hu S, Huang KM, Adams EJ, Loprinzi CL, and Maryam Lustberg MB. Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin Cancer Res. 2019 May 23. doi: 10.1158/1078-0432.CCR-18-2152.
  • Chen M, Neul C, Schaeffeler E, Frisch F, Winter S, Schwab M, Koepsell H, Hu S, Laufer S, Baker SD, Sparreboom A, and Nies A. Sorafenib activity and disposition in liver cancer does not depend on organic cation transporter 1 (OCT1). Clin Pharmacol Ther. 2019 doi: 10.1002/cpt.1588.
  • Drenberg CD, Shelat A, Orwick SJ, Li M, Jeon JY, Hu S, Buelow DR, Pioso M, Inaba H, Ribeiro RC, Rubnitz JE, Gruber TA, Guy RK, Baker SD. Integrated high-throughput screen to identify novel treatment leads for pediatric acute myeloid leukemia (AML). Nature Commun. 2019 10(1):2189.
  • Fu Q, Chen M, Hu S, McElroy CA, Mathijssen RH, Sparreboom A, Baker SD. Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jul 15;1090:43-51.
  • Hu S, Sprowl J. Strategies to reduce solute carrier-mediated toxicity. Clin Pharmacol Ther. 2018 104(5):799-802.
  • Leblanc AF, Sprowl JA, Alberti P, Chiorazzi A, Arnold WD, Gibson AA, Hong KW, Pioso MS, Chen M, Huang KM, Chodisetty V, Costa O, Florea T, de Bruijn P, Mathijssen RH, Reinbolt RE, Lustberg MB, Sucheston-Campbell LE, Cavaletti G, Sparreboom A, Hu S. OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. J Clin Invest. 2018 Feb 01;128(2):816-825.
  • Hu S, Leblanc AF, Gibson AA, Hong KW, Kim JY, Janke LJ, Li L, Vasilyeva A, Finkelstein DB, Sprowl JA, Sweet DH, Schlatter E, Ciarimboli G, Schellens J, Baker SD, Pabla N, Sparreboom A. Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity. Clin Transl Sci. 2017 10(5):412-420.
  • Drenberg CD, Gibson AA, Pounds SB, Shi L, Rhinehart DP, Li L, Hu S, Du G, Nies AT, Schwab M, Pabla N, Blum W, Gruber TA, Baker SD, Sparreboom A. OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Res. 2017 77(8):2102-2111.
  • Bins S, van Doorn L, Phelps MA, Gibson AA, Hu S, Li L, Vasilyeva A, Du G, Hamberg P, Eskens F, de Bruijn P, Sparreboom A, Mathijssen R, Baker SD. Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide. Clin Transl Sci. 2017 10(4):271-279.
  • Sprowl JA, Ong SS, Gibson AA, Hu S, Du G, Lin W, Li L, Bharill S, Ness RA, Stecula A, Offer SM, Diasio RB, Nies AT, Schwab M, Cavaletti G, Schlatter E, Ciarimboli G, Schellens JH, Isacoff EY, Sali A, Chen T, Baker SD, Sparreboom A, Pabla N. A phosphotyrosine switch regulates organic cation transporters. Nat Commun. 2016 7:10880.
  • Vasilyeva A, Durmus S, Li L, Wagenaar E, Hu S, Gibson AA, Panetta JC, Mani S, Sparreboom A, Schinkel AH and Baker S. Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a/1b. Cancer Res. 2015 75(13): 2729-2736.
  • Hu S, Mathijssen RH, de Bruijn P, Baker SD, Sparreboom A. Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br J Cancer. 2014 110(4):894-8.
  • Hu S, Niu H, Inaba H, Rubnitz J, Orwick S, Panetta JC, Furmanski BD, Schuetz J, Baker SD. The multikinase inhibitor sorafenib enhances the activity of cytarabine in a mouse nexograft model of acute myeloid leukemia (AML). J Natl Cancer Inst. 2011 103(11):893-9052011.
  • Hu S, Sprowl JA. Strategies to Reduce Solute Carrier-Mediated Toxicity. Clin Pharmacol Ther. 2018 Nov;104(5):799-802.
  • Fu Q, Chen M, Hu S, McElroy CA, Mathijssen RH, Sparreboom A, Baker SD. Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jul 15;1090:43-51.
  • Huang KM, Hu S, Sparreboom A. Drug transporters and anthracycline-induced cardiotoxicity. Pharmacogenomics. 2018 Jul 01;19(11):883-888.
  • Leblanc AF, Sprowl JA, Alberti P, Chiorazzi A, Arnold WD, Gibson AA, Hong KW, Pioso MS, Chen M, Huang KM, Chodisetty V, Costa O, Florea T, de Bruijn P, Mathijssen RH, Reinbolt RE, Lustberg MB, Sucheston-Campbell LE, Cavaletti G, Sparreboom A, Hu S. OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. J Clin Invest. 2018 Feb 01;128(2):816-825.
  • Drenberg CD, Gibson AA, Pounds SB, Shi L, Rhinehart DP, Li L, Hu S, Du G, Nies AT, Schwab M, Pabla N, Blum W, Gruber TA, Baker SD, Sparreboom A. OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Res. 2017 04 15;77(8):2102-2111.
  • Drenberg CD, Buaboonnam J, Orwick SJ, Hu S, Li L, Fan Y, Shelat AA, Guy RK, Rubnitz J, Baker SD. Evaluation of artemisinins for the treatment of acute myeloid leukemia. Cancer Chemother Pharmacol. 2016 06;77(6):1231-43.
  • Sprowl JA, Ong SS, Gibson AA, Hu S, Du G, Lin W, Li L, Bharill S, Ness RA, Stecula A, Offer SM, Diasio RB, Nies AT, Schwab M, Cavaletti G, Schlatter E, Ciarimboli G, Schellens JH, Isacoff EY, Sali A, Chen T, Baker SD, Sparreboom A, Pabla N. A phosphotyrosine switch regulates organic cation transporters. Nat Commun. 2016 Mar 16;7:10880.